April 19th 2024
“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Experts discuss future research on functional decline after partial nephrectomy
August 11th 2023"One of the things that we want to look at long-term is how the kidney being exposed to limited durations of warm ischemia compared to no ischemia at all affects longitudinal atrophy," says Carlos Muñoz-Lopez.
Race-modified equations contribute to disparity in partial nephrectomy use in black patients
July 10th 2023“Our findings show that race-modified equations account for some but not all of the disparity in partial nephrectomy use. We need to keep searching for answers to ensure people of all races receive appropriate care," said Christopher Weight, MD.
Financial toxicity is a growing concern in urologic oncology
June 23rd 2023"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.
Emulating target trials using observational evidence to inform clinical decision-making
June 2nd 2023"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.
Dr. Stifelman on retroperineal partial nephrectomy for anterior vs posterior renal tumors
May 30th 2023"Even though most urologists who do retroperitoneal surgery do it for posterior tumors, you actually can do it equally well with as equally good success for an anterior tumor," says Michael D. Stifelman, MD.
Study identifies biomarkers predictive of response to immunotherapy in patients with kidney cancer
April 7th 2023In combination, the number of immune cells in and around kidney tumors, the amount of dead cancer tissue, and the mutations of PBRM1 can serve as biomarkers of response to immunotherapy in patients with kidney cancer.
Disparities found in clinical trial participation for patients with renal cell carcinoma
April 3rd 2023“These disparities are concerning as the generalizability of clinical trial results relies on the assumption that the population of patients included in a clinical trial represents the overall population of patients with the disease," says Brian M. Shinder, MD.